Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Core Insights - Nasus Pharma Ltd. has received a No-Objection Letter from Health Canada for its planned Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation aimed at treating anaphylaxis [1][2]. Regulatory Milestone - The Health Canada authorization is a significant regulatory milestone for the NS002 development program, confirming the trial design, safety data, and manufacturing information [2]. Product Development - NS002 is being developed as a needle-free alternative to traditional epinephrine autoinjectors, addressing the challenges of needle fear and the inconvenience of carrying autoinjectors for patients with severe allergies [3][4]. - The proprietary Nasax® technology aims to deliver epinephrine effectively through a simple nasal spray, enhancing patient compliance and potentially improving treatment outcomes [3][4]. Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions, leveraging its proprietary powder-based intranasal (PBI) technology for rapid drug delivery [4].